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Background: Treatment with ipilimumab, a fully human anti-CTLA-4 antibody approved for the treatment of
advanced melanoma, is associated with some immune-related adverse events (irAEs) such as colitis (gastrointestinal
irAE, or GI irAE) and skin rash, which are managed by treatment guidelines. Nevertheless, predictive biomarkers that
can help identify patients more likely to develop these irAEs could enhance the management of these toxicities.
Methods: To identify candidate predictive biomarkers associated with GI irAEs, gene expression profiling was
performed on whole blood samples from 162 advanced melanoma patients at baseline, 3 and 11 weeks after the
start of ipilimumab treatment in two phase II clinical trials (CA184004 and CA184007). Overall, 49 patients
developed Grade 2 or higher (grade 2+) GI irAEs during the course of treatment. A repeated measures analysis of
variance (ANOVA) was used to evaluate the differences in mean expression levels between the GI irAE and No-GI
irAE groups of patients at the three time points.
Results: In baseline samples, 27 probe sets showed differential mean expression (≥ 1.5 fold, P ≤ 0.05) between the
GI irAE and No-GI irAE groups. Most of these probe sets belonged to three functional categories: immune system,
cell cycle, and intracellular trafficking. Changes in gene expression over time were also characterized. In the GI irAE
group, 58 and 247 probe sets had a ≥ 1.5 fold change in expression from baseline to 3 and 11 weeks after first
ipilimumab dose, respectively. In particular, on-treatment expression increases of CD177 and CEACAM1, two
neutrophil-activation markers, were closely associated with GI irAEs, suggesting a possible role of neutrophils in
ipilimumab-associated GI irAEs. In addition, the expression of several immunoglobulin genes increased over time,
with greater increases in patients with grade 2+ GI irAEs.
Conclusions: Gene expression profiling of peripheral blood, sampled before or early in the course of treatment
with ipilimumab, resulted in the identification of a set of potential biomarkers that were associated with occurrence
of GI irAEs. However, because of the low sensitivity of these biomarkers, they cannot be used alone to predict
which patients will develop GI irAEs. Further investigation of these biomarkers in a larger patient cohort is
warranted.
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Ipilimumab, a fully human monoclonal antibody that
blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) [1],
has been approved by the U.S. Food and Drug Adminis-
tration (FDA) and several other regulatory agencies for
the treatment of advanced metastatic melanoma (MM).
The efficacy of ipilimumab has been demonstrated in a
number of phase II and two phase III clinical trials in
MM patients, where a significant prolongation of overall
survival has been reported [2,3].
Treatment with ipilimumab is associated with a
spectrum of AEs which are immune mediated and called
immune-related adverse events (irAEs). Gastrointestinal
(GI) irAEs such as diarrhea and colitis are among the
most common ipilimumab-associated irAEs [4]. In most
cases the onset of GI irAEs occurs after the second or
third dose of ipilimumab [5] and these irAEs are
managed according to established treatment guidelines.
In a previous report, examination of colon biopsies in a
safety-focused clinical trial (CA184007) revealed abun-
dant focal neutrophilic cryptitis and neutrophilic infiltra-
tion in the lamina propria of affected tissues from
patients experiencing GI irAEs. Although administration
of high doses of steroids often leads to successful and
safe management of the majority of these irAEs [5-7],
identification of biomarkers that may predict (before or
soon after the start of the treatment) these irAEs might
improve patient care. In this context, peripheral blood
biomarkers would be preferred, since collection of
peripheral blood is less invasive than a colonic biopsy.
To understand the underlying causes of ipilimumab-
associated GI irAEs and identify potential predictive
biomarkers, gene expression profiling was performed on
whole blood samples collected from metastatic melan-
oma patients before and during ipilimumab treatment in
two phase II clinical trials, CA184004 and CA184007
[6,8]. A number of cell cycle- and immune-related genes
were found to have higher expression at baseline and
post-baseline in those patients who experienced GI
irAEs. In particular, increases in expression of neutrophil
activation markers, CD177 and CEACAM1, were found
to be associated with the occurrence of GI irAEs.
In addition, greater increases in the expression of
immunoglobulin-related genes were detected at weeks 3
and 11 in patients with GI irAEs than in those without.
These results are consistent with our understanding of the
mechanisms underlying ipilimumab-associated GI irAEs
and provide a list of potential peripheral blood biomarkers
for early prediction of these irAEs.
Methods
Study design
The multicenter, phase II clinical trial CA184004
enrolled 82 previously-treated or untreated patients withstage III (unresectable) or IV melanoma, randomized 1:1
into 2 arms to receive up to 4 intravenous infusions of
either 3 or 10 mg/kg ipilimumab every 3 weeks in an
induction phase. In trial CA184007, treatment-naïve or
previously treated patients with stage III (unresectable)
or IV melanoma (N= 115) received open-label ipilimumab
(10 mg/kg every 3 weeks for four doses) and were random-
ized to receive concomitant blinded prophylactic oral
budesonide (9 mg/d with gradual taper through week 16)
or placebo (4). Exclusion criteria included the use of any
immuno-suppressing treatments including corticosteroids
(patients on stable doses of hormone replacement
therapy were exempt), cyclosporine, mycophenolate mofetil
(CellCeptW), as well as chemotherapy and radiation, within
4 weeks prior to the first ipilimumab dose. Complete study
design, patient characteristics and endpoint reports of these
trials were described elsewhere [6,8]. Gene expression pro-
files from twenty patients in CA184078 [9] who were
treated with ipilimumab monotherapy at 10 mg/ml were
used as a confirmation data set for the present analysis.
These studies were conducted in accordance with the eth-
ical principles originating from the current Declaration of
Helsinki and consistent with International Conference on
Harmonization Good Clinical Practice and the ethical prin-
ciples underlying European Union Directive 2001/20/EC
and the United States Code of Federal Regulations, Title 21,
Part 50 (21CFR50). The protocols and patient informed
consent forms received appropriate approval by all Institu-
tional Review Boards or Independent Ethics Committees
prior to study initiation. All participating patients (or their
legally acceptable representatives) gave written informed
consent for these biomarker-focused studies.Adverse event and clinical activity evaluation
Safety was evaluated using the National Cancer Institute
Common Terminology Criteria for Adverse Events,
based on adverse events (AEs), physical examinations,
and clinical laboratory assessments. Drug-related gastro-
intestinal AEs consistent with immune-mediated events
and the intrinsic biological activity of ipilimumab were
examined and reported. Adverse events were recorded
based on MedDRA v10.0 system organ class and Pre-
ferred Terms. Clinical activity (CA) was defined as con-
firmed complete response, confirmed partial response,
or stable disease ending not earlier than 24 weeks from
date of first ipilimumab dose. A complete description of
irAE and CA evaluations for these trials has been
reported elsewhere [6,8].
Absolute peripheral blood neutrophil count (APBNC)
Neutrophils were quantified as a component of the
standard hematology panel. Absolute neutrophil counts
were available at various time points for most patients.
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Whole blood samples for gene expression profiling were
collected just prior to first dose of ipilimumab (baseline),
and 3 and 11 weeks after first ipilimumab dose. Total
RNA was extracted from whole blood samples using the
PAXgene Blood RNA MDX kit with a BioRobot
Universal System (Qiagen, Valencia, CA), and purified
by RNeasy MinElute Cleanup kit using QIAcube
(Qiagen, Valencia, CA). RNA concentration was mea-
sured by NanoDrop spectrophotometer and RNA integ-
rity was evaluated on the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). Complementary
DNA preparation and hybridization on HT-HG-U133A
96-array plates followed manufacturer’s protocols (Affymetrix,
Santa Clara, CA). Affymetrix raw data (.CEL files) were
normalized with the robust multi-array analysis (RMA) al-
gorithm, obtained from www.bioconductor.org, version
1.20.2. Appropriate Affymetrix control probe sets were ex-
amined to ensure quality control for the cDNA synthesis
and hybridization steps. Principal component analysis
(PCA) was subsequently performed to detect outlier
samples (single samples that account for a high degree
of variation in the data). No sample was removed as an
outlier. Anti-log RMA values were used in subsequent
statistical analyses. For the combined data from studies
CA184004 and CA184007, 12518 of the 22215 non-
control probe sets had maximum expression level (RMA
normalized) of less than 32. These probe sets, with low ex-
pression levels across all samples, were excluded from fur-
ther analysis.
Gene expression data analyses
GI irAE status was available for all 197 treated patients.
Gene expression data were available for 188 of these pa-
tients. For 162 of the patients, expression data were
available for at least 2 of the 3 time points. Only these
patients were included in subsequent analyses. Of these
patients, 113 were classified in a No-GI irAE group,
which included patients with a worst-grade GI irAE of 0
or 1. A total of 49 patients with grade 2 or greater (grade
2+) GI irAEs were classified in a GI irAE group. For the
No-GI irAE and GI irAE groups, respectively, baseline
expression data were available for 108 and 49 patients,
week 3 data were available for 108 and 47 patients, and
week 11 data were available for 78 and 30 patients.
A repeated measures analysis of variance (ANOVA)
model was fit in Partek Genomics Suite 6.6 (www.
partek.com), with anti-log normalized expression level as
dependent variable. Explanatory variables included pa-
tient, time point within patient as a 3-level factor, and
binary GI irAE status, with no time-by-status inter-
action. Because GI irAEs were observed in all treatment
arms, and because of the relatively small sample sizes in
individual trials, data from patients in the two trials werecombined to increase statistical power to detect associa-
tions. Statistical inference based on this model focused
on two hypothesis tests: a test of the null hypothesis that
mean gene expression (averaged over time) was the
same in the two GI irAE status groups, and a test of the
null hypothesis that mean gene expression (averaged
over GI irAE status) was the same for the three time
points. An uncorrected P value of 0.05 was used as a
cutoff to select probe sets with mean expression differ-
ences between comparison groups. The qvalue package
(v1.20.0) in the R statistical computing environment
(v2.15.0, http://www.r-project.org) was used to estimate
false discovery rates (FDRs). Expression of selected genes
was confirmed by quantitative polymerase chain reaction
(qPCR) as described previously [10] using pre-designed
probes.
Gene pathway analysis
Functional interpretation of differentially expressed
genes was computed using Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems), as described previ-
ously [10].
Results
Gene expression profile of pre-treatment samples
Expression of each of 9697 non-control probe sets was
analyzed individually. Genes associated with GI irAE sta-
tus (grade 2+ vs. not) were selected by assessing the dif-
ference in mean pre-treatment expression between the
GI and No-GI irAE groups. Two selection criteria were
applied: a P value ≤ 0.05 for the hypothesis test compar-
ing the GI and No-GI irAE groups, and a minimum
mean pre-treatment expression ratio of 1.5. For these
tests, the P value threshold of 0.05 corresponded to an es-
timated FDR of 0.50. A set of 27 probe sets representing
24 unique genes met these criteria (Additional file 1:
Table 1A). This list included a number of immune-
related genes, such as CD3E, IL2RG [11], CD37 [12],
CD4, IL32 [13], and RAC2 [14]; cell cycle- and
proliferation-associated genes such as SPTAN1 [15],
BANF1 [16], BAT1 [17], PCGF1 [18], FP36L2 [19],
and WDR1 [20]; and genes involved in intracellular
vesicle trafficking such as PICALM [21], SNAP23
[21], and VAMP3 [22]. Some of these molecules such,
as IL32, SNAP23 and RAC2, have been reported
either to be present in neutrophils or to regulate their
function [13,14,21].
Gene expression profiles of post-baseline samples
To identify early on-treatment predictors of ipilimumab-
associated GI irAEs, post-baseline expression levels of
the 9697 non-control probe sets were compared be-
tween the GI irAE and No-GI irAE groups. Thirty five
and 47 probe sets were identified to have a mean
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samples, respectively, and a P value ≤ 0.05 (FDR = 0.50)
for the hypothesis test comparing the GI and No-GI
irAE groups. Since most ipilimumab-associated GI irAEs
occur after the second or third dose of ipilimumab, the
35 probe sets differentially expressed at week 3 are of
particular interest, as they might serve as early predic-
tors to help identify patients who experience GI irAEs
after the second dose, given at week 3 (Additional file 1:
Table 1B). The probe set that exhibited the largest differ-
ential expression corresponded to the neutrophil-specific
marker, CD177, a glycosyl-phosphatidylinositol (GPI)-
linked cell surface molecule [23]. There was no differ-
ence in baseline expression of CD177 between patients
in the GI and No-GI irAE groups. However, significantly
higher CD177 expression was found after only one dose
of ipilimumab in the GI irAE group [12.2 fold higher in
the GI irAE group than in the No-GI irAE group at
week 3 (P = 7.6E-03)]. In addition, increase in mean
expression of CD177 from baseline to week 3 was much
greater in the GI irAE group than in the No-GI irAE
group (Additional file 1: Table 2). The mean increase in
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Figure 1 CD177 expression during ipilimumab treatment. (A) Mean ex
experienced grade 2+ gastrointestinal immune-related adverse events (GI i
showing clinical activity (CA) or not (No-CA) also are plotted; (B) Mean exp
experienced grade 2+ GI irAE, or did not (No-GI irAE), and mean absolute p
period, by worst-grade GI irAE (bars); (C) CD177 expression level (RMA-norm
(D) CD177 expression level (anti-log RMA-normalized value) at week 3 vers
describe the worst grade of GI irAE reported during the course of treatmen
experienced a fatal grade-4 GI irAE.activity (CA) of ipilimumab (P = 0.23) (Figure 1A). Ex-
pression levels of CD177 in these samples were con-
firmed by quantitative PCR, showing statistically
significant differences between the GI irAE and No-GI
irAE groups (unadjusted P < 0.005) or changes over time
(unadjusted P < 0.0001). These data suggest that CD177
was not only a potential early predictor of GI irAEs but
that increase in CD177 gene expression might also be a
consequence of treatment with ipilimumab independent
of its clinical activity.Changes in CD177 expression in relation to peripheral
blood absolute neutrophil count (PBANC)
Since CD177 is a neutrophil surface marker, we exam-
ined the relationship between PBANC and expression
levels of CD177. Mean PBANC increased gradually with
ipilimumab treatment, with the largest apparent in-
creases occurring between weeks 9 and 11 in patients
with higher-grade GI irAE (Figure 1B, bars). The
increase in mean expression of CD177 preceded any sig-
nificant increase in PBANC (Figure 1B, lines), suggesting
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ment than PBANC.
Evaluation of CD177 as an early predictor of GI irAEs
Expression of CD177 at week 3 had large inter-individual
variability, with considerably higher values in 7 patients
than in the rest (Figure 1C). All seven patients with high
levels of CD177 expression (RMA-normalized expression
level ≥ 8) at week 3 had grade 2+ GI irAEs during the
course of treatment, suggesting high specificity of this bio-
marker above this threshold. However, many patients with
grade 2+ GI irAEs had a normalized expression level < 8 for
CD177 at week 3, suggesting low sensitivity of the
biomarker in predicting GI irAEs (Additional file 2: Figure
S1). In week 11 post-baseline samples, high expression
levels of CD177 were found in both the GI irAE and No-GI
irAE groups. Many patients with grade 2+ GI irAEs had
already discontinued treatment before this time point, so
the data from week 11 might be biased by informative
drop-out.
We also explored the timing of the onset of GI irAEs
in individual patients to establish the value of CD177 ex-
pression as an early predictor. Out of 44 patients with
grade 2+ GI irAEs who had matching gene expression
data at week 3, 6 patients reported the first GI irAE be-
fore or on day 21 ± 3 days (the nominal date of blood
sample collection), whereas the other 38 patients had GI
irAEs reported after this date (Figure 1D). The four
highest values of CD177 expression were detected in pa-
tients who reported the first grade 2+ GI irAE between
days 26 (2–5 days after blood sample collection) and 43
after receiving the first dose of ipilimumab. Of note, one
of the patients who had high CD177 expression at week
3 reported a grade 2 GI irAE on day 72 (Figure 1D,
marked in gray shade circle), but progressed to a grade 4
which ultimately led to fatal GI perforation. These data
suggest that, although considerable increase in CD177
gene expression was closely associated with the onset of
GI irAEs, early increases might also predict GI irAEs
that could develop much later. However, since CD177
had low sensitivity, this biomarker could not identify
most future GI irAEs.
Association between expression of CD177 and other
neutrophil-associated genes
CD177 is a glycoprotein expressed by neutrophils,
neutrophilic metamyelocytes, and myelocytes, but
not by any other blood cells [24,25]. Therefore we
specifically searched for other neutrophil-associated
genes, to better understand the implication of this
granulocyte subtype as an early predictor of GI
irAEs. These included genes encoding for granule-
associated proteins such as olfactomedin 4 (OLFM4)
[26], azurocidin 1 (AZU1), lactoferrin (LTF) [27],cathelicidin (CAMP), myeloperoxidase (MPO) [28],
bactericidal/permeability increasing protein (BPI), defensin
(DEFA4) [29], neutrophil elastase (ELANE) [30], cathepsin
G (CTSG) [30], CEACAM6, CEACAM8 [31], and
CEACAM1 (which mediates neutrophil adhesion to endo-
thelial cells and facilitates their transmigration into tissues)
[32]. The GeneChip HT-HG-U133A includes probe sets
for many of these genes Additional file 1: Table S3.
Although an apparent greater expression of each of these
genes was found in those samples with high levels of
CD177 expression (Figure 2A), only the expression of
CEACAM1 was significantly linearly correlated with that
of CD177 at week 3 (r = 0.75, P = 7.2E-30 between
219669_at, probe set for CD177, and 206576_s_at, probe
set for CEACAM1). Consequently, the pattern of mean
gene expression of CEACAM1 over time was similar to
that for CD177 (Figures 1A and 2B).
Pathway analysis of changes in gene expression from
baseline to week 11
Fifty-eight and 247 probe sets were identified as
having at least a 1.5-fold change from baseline in
week 3 and 11 samples, respectively, and P ≤ 0.05
(FDR = 0.055) for the test of a time effect on expres-
sion (Additional file 1: Tables 2 and S1). We
performed a pathway analysis using the IPA software
on the 247 differentially expressed probe sets since
the size of this gene set was amenable to such
analysis. The top biological processes that exhibited
changes during ipilimumab treatment included path-
ways of cell proliferation and metabolism, and
immune-related pathways such as IL-10 signaling,
IL-8 signaling, and B cell development Figure 3A).
Increase in expression of immunoglobulin genes in post-
baseline samples
While CD177 exhibited the largest change from
baseline at both time points, immunoglobulin-
related genes dominated both lists, including IGHA1,
IGHA2, IGHG1, and IGHV4-31, all of which showed
significant increases in expression 11 weeks after
baseline. Slight increases in expression of some of
these genes were already apparent in week 3 sam-
ples, suggesting an early onset of antibody response
with much larger expansion at later time points
(Additional file 1: Table 2 and Figure 3B). Notably,
increases in expression of these genes over time
were more prominent in the GI irAE groups than in
the No-GI irAE group. There was no corresponding
increase in B-cell marker genes (such as CD20),
suggesting that the cell types responsible for the in-
creased expression of immunoglobulin genes may
not have been B-cells, but later-stage B-lineage cells
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Figure 2 Expression of granule-associated genes. (A) Mean expression level for samples with high CD177 expression (> 256) versus that for
samples with low CD177 expression (< 32), for each of the 9697 probe sets passing the low-expression filter. Each point represents one probe set.
Blue squares highlight CD177 and 19 probe sets for 13 unique neutrophil granule-associated genes. Diagonal reference lines indicate mean
expression ratios of 4, 2, 1, 0.5, and 0.25. Expression of genes with points above the central dashed line was positively associated with CD177
expression. (B) Mean gene expression (anti-log RMA-normalized value) of CEACAM1 (probe set: 206576_s_at) during ipilimumab treatment in
patients with (GI irAE) or without (No-GI irAE) a grade 2 or greater GI irAE.
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(CA184078)
Whole blood samples from the clinical study CA184078
were independently analyzed using the same statistical
model. In this study, 20 patients were treated with
ipilimumab monotherapy at 10 mg/kg every 3 weeks for
4 doses. The mean CD177 expression ratio comparing
GI irAE and No-GI irAE groups at week 3 and 11 was
4.3 and 12.0, respectively, with no significant difference
at baseline. In the GI irAE group, the mean fold change
from baseline to week 3 and 11 was 4.8 and 15.3,
respectively. By contrast, in the No-GI irAE group, these
changes were negligible (1.1 and 1.2, respectively). Ex-
pression changes similar to those seen in the other two
studies were observed for CEACAM1 and most of the
granule-associated genes, with significant changes from
baseline to week 11 in the GI irAE group but not in the
No-GI irAE group (Additional file 1: Table S2).
Discussion
Treatment with ipilimumab has been shown to prolong
overall survival in advanced melanoma patients in 2
phase 3 trials [2,34]. Gastrointestinal irAEs such as diar-
rhea and colitis are among the most common and some-
times severe forms of adverse events associated with
ipilimumab. These adverse events are currently managed
following treatment guidelines. However, identification
of predictive biomarkers is important as it may enhance
the management of these toxicities and improve patient
care. The present study was undertaken to identify such
biomarkers in peripheral blood. In a previous report of
the CA184007 trial in which colonic biopsies were col-
lected, changes in the colonic mucosa following onset ofdiarrhea appeared more severe than those observed in
the pre-specified biopsies following the first dose of
ipilimumab. Histopathologic examination of the biopsies
revealed active colitis with marked neutrophilic infiltra-
tion into lamina propria to be the most striking charac-
teristic of the affected tissue. In these biopsies, foci of
neutrophilic cryptitis, crypt abscesses, glandular destruc-
tion, and erosions of the mucosal surface were also
apparent early after the start of treatment in those
patients who presented with GI irAE symptoms [5].
However, collection of colonic biopsies is considered an
invasive procedure and therefore, peripheral-blood
surrogate markers would be preferred.
GI irAE onset is most commonly observed after the
second or third doses of ipilimumab. Gene expression
profiling using pre-treatment blood samples identified a
few immune-related genes with higher baseline expres-
sion in patients who developed GI irAEs than in those
who did not, including CD3E, IL2RG, CD4, CD37 and
IL-32. Interleukin 32 (natural killer protein-4) might be
the most interesting gene from this list, as this cytokine
has been reported to play a central role in acute flares of
inflammatory bowel disease [35], as well as other auto-
immune diseases such as Rheumatoid arthritis [36]. IL32
is selectively expressed by activated cytotoxic T and nat-
ural killer (NK) cells [37], potentiates the effect of IL-2
and IL-18 and activates the innate immune system
(monocytes and macrophages) to secrete chemotactic
factors such as tumor necrosis factor-alpha (TNF-α),
CXCL2 (11), and IL-8. A direct effect of IL-8 on the acti-
vation of neutrophils, the expression or activation of ad-
hesion molecules in the neutrophil cell membrane, and
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Figure 3 Expression of immune-related genes during ipilimumab treatment. (A) Functional interpretation of genes differentially expressed
between baseline and week 11, as computed by Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems). The P value reflects the
significance of the enrichment of input genes in the functional category or pathway of interest. For every canonical pathway, IPA also provides
the ratio of the number of genes from the input list that are annotated to the pathway to the total number of genes annotated to the pathway.
(B) Fold change over time in expression of immunoglobulin-associated genes in the GI irAE and No-GI irAE groups. Genes shown were selected
from the top 50 genes having the most prominent mean differences in on-treatment expression between the two GI irAE groups.
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though treatment-induced changes in the expression of
IL-8 were not significant, pathway analysis found IL-8
signaling to be one of the top 10 pathways changed dur-
ing treatment (Figure 3A).
An increase in expression of neutrophil-associated
genes was noticeable shortly after the start of treatment.
In particular, significantly greater mean expression of the
neutrophil surface marker CD177 was detected in a sub-
set of patients who experienced GI irAEs of grade 2 orgreater. Neutrophil granulocytes are the most abundant
type of white blood cells in mammals and form an es-
sential part of the innate immune system. During the
acute phase of inflammation, particularly as a result of
bacterial infection, environmental exposure [40], and
some cancers [41,42], neutrophils are among the first-
responders of inflammatory cells to migrate towards the
site of inflammation. They transmigrate through the
blood vessels, then through interstitial tissue, following
chemical signals such as IL-8, C5a, and Leukotriene B4
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marker for neutrophils [24,25] and is up-regulated upon
neutrophil activation during acute inflammatory re-
sponses toward stimuli such as bacterial infections [44].
Significant increase in the mean expression of this
marker was detected in patients who experienced mod-
erate to severe GI irAEs, independently from their clin-
ical response to ipilimumab. Indeed, the seven patients
with the highest expression levels of CD177 (normalized
expression level > 8) at week 3 were those who already
had or would experience GI irAEs within a few days to
three weeks after that time point. Currently, GI irAEs
during ipilimumab treatment are managed, according to
treatment guidelines, by cessation of ipilimumab in com-
bination with treatment with corticosteroids or TNF-α
blockade. CA184004 was one of the earlier ipilimumab
monotherapy trials, where these guidelines were not yet
fully in place. In that trial, two patients died of severe GI
irAEs and intestinal perforation. One of these patients
provided both baseline and week 3 blood samples for
gene expression analysis. A 42.5-fold increase in CD177
expression from baseline to week 3 was apparent almost
50 days before the onset of the first GI irAE episode,
suggesting the early predictive value of this biomarker
for severe GI irAEs. CD177 has been shown to recognize
an endothelial cell junction molecule, platelet endothelial
cell adhesion molecule-1 (PECAM-1), which contributes
to interactions between neutrophils and endothelial cells,
mediating trans-endothelial migration in the context of
inflammatory cell recruitment [45].
Another marker expressed by activated neutrophils,
CEACAM1, also showed a consistent increase in mean
expression from baseline to 3 or 11 weeks after first
ipilimumab dose, with a greater increase in the GI irAE
group. Whereas CD177 is mostly an activation marker
for neutrophils, CEACAM1 mediates adherence of acti-
vated neutrophils and other hematopoietic cells (NK and
T cells) to cytokine-activated endothelium, [46,47] and
has been suggested to play a role in immune-mediated
diseases of the intestine. Elevated CEACAM1 expression
has been reported in T cells of the lamina propria of
small intestine in patients with celiac disease and in the
large intestine of those with inflammatory bowel disease
(IBD) [48].
The apparent association between neutrophil count,
CD177 gene expression, and ipilimumab-associated GI
irAEs led us to search for other neutrophil-associated
genes in the microarray data. Degranulation is the
process by which neutrophils release an assortment of
proteins [49] such as MPO, DEFA4 [29] and ELANE
[30] into the extracellular space. Most of these genes
were included in a neutrophil module reported by
Chaussabel et al. [33]. Although a trend for greater ex-
pression of these genes was found in those samples withthe highest levels of CD177 expression (Figure 2A),
there was no statistically significant linear correlation
between their expression and that of CD177 (data not
shown). In fact, the mean expression of most of these
genes in week 3 samples was lower than baseline
(Additional file 1: Table 2, left panel), when the greatest
increase in CD177 was detected in some patients,
suggesting that their expression might be repressed dur-
ing the early neutrophil activation event. Conversely, a
significant increase in the mean expression of these
genes was observed at week 11 (Additional file 1: Table
S1), supporting the notion that the degranulation
process follows that of the neutrophil activation event.
These observations were also confirmed in another data
set from an independent ipilimumab clinical trial,
CA184078, in which higher mean expression of CD177
and CEACAM1 were found in the GI irAE group.
In addition, our list of potential early predictors of GI
irAEs shared a number of common elements with sets
of genes reported to confer resistance to intravenous
corticosteroid therapy in children with ulcerative colitis
[50]. Genes shared between the two studies included
CD177, CEACAM1, OLFM4, MMP8, BPI, CLC, HP, and
LCN2. In that study, post-baseline samples were col-
lected only three days after the start of the corticosteroid
treatment with significant differential expression of these
genes between the steroid-resistant and sensitive pa-
tients. In our study, the earliest post-baseline blood sam-
ples were collected 3 weeks after the first dose of
ipilimumab, and the major changes in gene expression
occurred within this time period, suggesting that it
might be possible to detect this predictive profile at an
even earlier time within this period. In any event, these
changes tended to precede significant increases in the
number of peripheral neutrophils, suggesting that the
proliferation of neutrophils occurs after the activation
event and that changes in gene expression may serve as
more sensitive biomarkers than increase in peripheral
blood absolute neutrophil count (PBANC).
Another interesting finding in our analysis was the
considerable increase in the number and expression of
immunoglobulin-related genes at 3 and 11 weeks after
first dose of ipilimumab in patients who had GI irAEs.
This is in accordance with previous reports on the in-
hibitory effects of CTLA-4 on immunoglobulin and
cytokine production by plasma cells [51] or its inhibitory
effect on CD4+ T cells that mediate T cell help to B cells
during antibody production. CTLA-4 blockade by
ipilimumab is likely to reduce this inhibition. In healthy
people, the humoral response to enteric flora is
maintained in homeostasis. Dysregulation of this homeo-
stasis, manifested as increasing antibody levels to select
enteric microorganisms, is characteristic of gastrointes-
tinal disorders such as IBD but not acute GI inflammation
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from the CA184007 trial, ipilimumab was found to induce
antibody responses to selected enteric flora such as
Pseudomonas anti-I2, Saccharomyces cerevisiae, and CBir
flagellin. However, no strong association between a posi-
tive level of antibody responses toward these specific
bacteria and GI irAEs was observed. Although gene ex-
pression profiling could not provide information re-
garding the specificity of the induced antibodies, it still
indicates that in patients experiencing GI irAEs, the
immunoglobulin production machinery had been
turned on. In the absence of infections by external
pathogens, this response may well be due to the gener-
ation of antibodies to self antigens or those expressed
by the intestinal flora.
Conclusions
We have identified early changes in gene expression in
patients treated with ipilimumab that in some patients
might predict the incidence of later GI irAEs. These
gene expression changes, together with prior histopatho-
logic examination of the affected tissue, point to an
important role of neutrophils in the onset of GI irAEs in
these patients. High expression of CD177 at week 3 was
a very specific biomarker for grade 2+ GI irAEs, as all
patients who had no such event displayed expression
levels below a certain threshold (normalized expression
level = 8). However, because of its low sensitivity as a
biomarker, CD177 expression alone cannot be used to
predict which patients will develop GI irAEs, which may
occur in patients with low CD177 expression. The earli-
est on-treatment sample collection was 3 weeks after
first ipilimumab dose. Therefore it is not clear how
much increases in CD177 expression preceded the onset
of GI irAEs. This study identified potential biomarkers
of ipilimumab toxicity that have biological plausibility.
However, validation in a larger controlled trial is needed
to assess potential clinical utility.
Additional files
Additional file 1: Table 1. Lists of potential predictive or early-
predictive biomarkers. (A) Probe sets with ≥ 1.5-fold greater mean
baseline expression in blood samples from patients with grade 2+ GI
irAEs than in those from patients with no grade 2+ GI irAE (highlighted
column). Mean expression ratio in the post-baseline samples as well as
P values for the test of a difference at baseline in mean expression
between the two GI irAE groups also are shown. (B) Probe sets with a
mean expression ratio of at least 1.5 for the comparison of the GI irAE
and No-GI irAE groups at week 3 (highlighted column). Mean expression
ratio at other time points as well as P values for the test of a difference in
week 3 mean expression between the two GI irAE groups also are
shown. Mean expression ratio: positive values give (mean expression in
the GI irAE group)/(mean expression in the No-GI irAE group); negative
values give negative of (mean expression in the No-GI irAE group)/(mean
expression in the GI irAE group). Table 2. Lists of potential
pharmacodynamic biomarkers. Probe sets with ≥ 1.5-fold change inmean gene expression from baseline to week 3 (left panel) or week 11
(right panel; only the top 58 probe sets shown) in the GI irAE group
(highlighted columns). Fold changes in the No-GI irAE group as well as
P values for the test of a difference between baseline and post-baseline
expression also are shown. Mean fold change: positive values give mean
of (post-baseline expression)/(baseline expression); negative values give
negative mean of (baseline expression)/(post-baseline expression). Table 3.
Granule-associated gene expression profiles. (A) Mean expression ratio
comparing the GI irAE and No-GI irAE groups for granule-associated genes
at each time point. P value for the test of a difference in mean expression
between the two GI irAE groups (averaged over the three time points) also
is shown. (B) Mean fold change from baseline (BL) in the GI irAE and No-GI
irAE groups for granule-associated genes. P value for the test of a difference
in mean expression among the three time points (averaged over the two
groups) is shown. For definitions of “mean expression ratio” and “mean fold
change”, see legends for Tables 1 and 2, respectively. Table S1. Complete
list of potential pharmacodynamic biomarkers. Probe sets with ≥ 1.5-fold
mean change in gene expression from baseline to week 11 in the GI irAE
group (highlighted column). Fold changes in the No-GI irAE group as well
as P values for the test of a difference between baseline and post-baseline
expression also are shown. Mean fold change: positive values give mean of
(post-baseline expression)/(baseline expression); negative values give
negative mean of (baseline expression)/(post-baseline expression). Table S2.
Granule-associated gene expression profiles in CA184078. (A) Mean
expression ratio comparing the GI irAE and No-GI irAE groups for granule-
associated genes at each time point. P value for the test of a difference in
mean expression between the two GI irAE groups (averaged over the three
time points) also is shown. (B) Mean fold change from baseline (BL) in
the GI irAE and No-GI irAE groups for granule-associated genes. P value for
the test of a difference in mean expression among the three time points
(averaged over the two groups) is shown. Mean expression ratio: positive
values give (mean expression in the GI irAE group)/(mean expression in
the No-GI irAE group); negative values give negative of (mean expression
in the No-GI irAE group)/(mean expression in the GI irAE group).
Mean fold change: positive values give mean of (post-baseline
expression)/(baseline expression); negative values give negative
mean of (baseline expression)/(post-baseline expression).
Additional file 2: Figure S1. ROC curve of CD177 expression at week 3
as a predictor of GI irAE. The plot included 155 patients with known GI
irAE status and CD177 expression values.Abbreviations
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